Science Explorer Back to mapMap
Discussion
Company · Malvern · United States

VenatoRx Pharmaceuticals (United States)

Research works
36
▲ 174% vs 2018-21
Citations
832
23.0 per fractional work
Top-10% rate
15.6%
all institutions 10.0%
Open access
76%
world 40%
International
22%
world 18%

Not ranked overall: VenatoRx Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does VenatoRx Pharmaceuticals (United States) work in?

In all years, 56% of research at VenatoRx Pharmaceuticals (United States) is in Life Sciences, 37% in Health Sciences. Its largest fields are Medicine (37%), Biochemistry, Genetics and Molecular Biology (33%), Immunology and Microbiology (11%). It does 2.7× the world's share of Life Sciences.

Life Sciences: 20 fractional works · 55.7% of its workBiochemistry, Genetics and Molecular Biology: 12 fractional works · 32.9% of its workMolecular Medicine: 6 fractional works · 16.9% of its workMolecular Biology: 4 fractional works · 10.2% of its workEndocrinology: 1 fractional works · 2.3% of its workGenetics: 1 fractional works · 2.0% of its workClinical Biochemistry: 0 fractional works · 0.8% of its workCell Biology: 0 fractional works · 0.5% of its workBiotechnology: 0 fractional works · 0.3% of its workImmunology and Microbiology: 4 fractional works · 11.5% of its workApplied Microbiology and Biotechnology: 2 fractional works · 6.1% of its workImmunology: 2 fractional works · 5.1% of its workSmaller subfields together: 0 fractional works · 0.3% of its workNeuroscience: 3 fractional works · 9.1% of its workCellular and Molecular Neuroscience: 2 fractional works · 6.7% of its workNeurology: 0 fractional works · 0.9% of its workCognitive Neuroscience: 0 fractional works · 0.6% of its workDevelopmental Neuroscience: 0 fractional works · 0.5% of its workBehavioral Neuroscience: 0 fractional works · 0.3% of its workAgricultural and Biological Sciences: 1 fractional works · 1.7% of its workPlant Science: 1 fractional works · 1.7% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.5% of its workPharmacology: 0 fractional works · 0.5% of its workHealth Sciences: 13 fractional works · 36.6% of its workMedicine: 13 fractional works · 36.6% of its workPharmacology: 5 fractional works · 14.6% of its workEpidemiology: 3 fractional works · 8.1% of its workOncology: 1 fractional works · 2.6% of its workHepatology: 1 fractional works · 1.8% of its workInfectious Diseases: 1 fractional works · 1.6% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 1.5% of its workHematology: 0 fractional works · 1.1% of its workEmergency Medicine: 0 fractional works · 0.9% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 0.9% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.5% of its workPathology and Forensic Medicine: 0 fractional works · 0.5% of its workPsychiatry and Mental health: 0 fractional works · 0.5% of its workCritical Care and Intensive Care Medicine: 0 fractional works · 0.3% of its workGenetics: 0 fractional works · 0.3% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.3% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.2% of its workMicrobiology: 0 fractional works · 0.2% of its workOtorhinolaryngology: 0 fractional works · 0.2% of its workPulmonary and Respiratory Medicine: 0 fractional works · 0.2% of its workPhysical Sciences: 3 fractional works · 7.1% of its workEnvironmental Science: 1 fractional works · 3.7% of its workPollution: 1 fractional works · 3.7% of its workChemistry: 1 fractional works · 3.0% of its workOrganic Chemistry: 1 fractional works · 1.6% of its workAnalytical Chemistry: 0 fractional works · 0.9% of its workSpectroscopy: 0 fractional works · 0.5% of its workMaterials Science: 0 fractional works · 0.4% of its workMaterials Chemistry: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.1% of its workSocial Sciences: 0 fractional works · 0.6% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.3% of its workEconomics and Econometrics: 0 fractional works · 0.3% of its workSocial Sciences: 0 fractional works · 0.3% of its workGender Studies: 0 fractional works · 0.3% of its workALL ITS WORKVenatoRxPharmaceuticals…36fractional works, all years
Life Sciences56%Physical Sciences7%Health Sciences37%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 11 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology1232.9%
    2. Immunology and Microbiology411.5%
    3. Neuroscience39.1%
    4. Agricultural and Biological Sciences11.7%
    5. Pharmacology, Toxicology and Pharmaceutics00.5%
    1. Medicine1336.6%
    1. Environmental Science13.7%
    2. Chemistry13.0%
    3. Materials Science00.4%
    1. Economics, Econometrics and Finance00.3%
    2. Social Sciences00.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.64× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 6.85× its world share, 7 worksBiochemistry, Geneti…Immunology and Microbiology: 9.05× its world share, 2 worksImmunology and Micro…Chemistry: 2.05× its world share, 1 worksChemistryEnvironmental Science: 0.56× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.23× its world share, 0 worksMaterials ScienceMedicine: 2.31× its world share, 8 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 9.1×. Every wedge is a field page.

All 7 fields, with their numbers
  1. Immunology and Microbiology9.05×2 works
  2. Biochemistry, Genetics and Molecular Biology6.85×7 works
  3. Medicine2.31×8 works
  4. Chemistry2.05×1 works
  5. Agricultural and Biological Sciences0.64×0 works
  6. Environmental Science0.56×0 works
  7. Materials Science0.23×0 works

Who are the top researchers at VenatoRx Pharmaceuticals (United States)?

Ranked on the quality score, Daniel C. Pevear, David A. Six and Denis M. Daigle lead among researchers whose main affiliation is VenatoRx Pharmaceuticals (United States).

  1. 1 Daniel C. Pevear United States · #254,805 worldwide 5.3k citations · 82 works
  2. 2 David A. Six United States · #703,617 worldwide 5.1k citations · 61 works
  3. 3 Denis M. Daigle United States · #1,036,556 worldwide 1.9k citations · 36 works
  4. 4 Greg Moeck United States · #1,312,038 worldwide 4k citations · 103 works
  5. 5 Cullen L. Myers United States · #1,546,768 worldwide 499 citations · 15 works
  6. 6 Carlos Fernando de Oliveira United States · #2,668,999 worldwide 437 citations · 16 works
  7. 7 Brittany Miller United States · #2,884,088 worldwide 35 citations · 17 works
  8. 8 Allison L. Zulli United States · #3,011,097 worldwide 587 citations · 26 works
  9. 9 Luigi Xerri United States · #3,168,717 worldwide 861 citations · 46 works
All ranked researchers at VenatoRx Pharmaceuticals (United States)

What are the most cited papers from VenatoRx Pharmaceuticals (United States)?

The most cited paper from VenatoRx Pharmaceuticals (United States) is "Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain" (JM Roberts-Lewis, MJ Savage, VR Marcy et al., 1994), with 322 citations. Next come "VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa" (220) and "Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics" (153).

Most cited papers
#PaperReleasedCitations
1 Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain JM Roberts-Lewis, MJ Savage, VR Marcy et al. · Journal of Neuroscience Open access Jun 1994 322
2 VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa Jodie C. Hamrick et al. · Antimicrobial Agents and Chemotherapy Open access 18 Dec 2019 220
3 Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics Phillip E. Klebba, Salete M. Newton, David A. Six et al. · Chemical Reviews ReviewOpen access 16 Mar 2021 153
4 Recent Advances in Amorphous Solid Dispersions: Preformulation, Formulation Strategies, Technological Advancements and Characterization Srushti M. Tambe, Divya D. Jain, Saikishore Meruva et al. · Pharmaceutics Open access 16 Oct 2022 127
5 International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function Hubert Vaudry, Jérôme Leprince, David Chatenet et al. · Pharmacological Reviews Open access 23 Dec 2014 106
All 70 most cited papers, with filters and sorting

Which keywords describe research at VenatoRx Pharmaceuticals (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Antibiotic Resistance, Antimicrobial Resistance, ESKAPE Pathogens, Multidrug-Resistant Bacteria, Antibiotic Pharmacokinetics, Critically Ill Patients, Epidemiology and Drug Resistance.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 29 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 29 words, with their numbers
  1. Antibiotic Resistance10▲ 66×7 topics
  2. Antimicrobial Resistance6▲ 69×3 topics
  3. ESKAPE Pathogens6▲ 319×1 topic
  4. Multidrug-Resistant Bacteria6▲ 319×1 topic
  5. Epidemiology5▲ 3.6×12 topics
  6. Antibiotic Pharmacokinetics5▲ 308×1 topic
  7. Critically Ill Patients5▲ 308×1 topic
  8. Drug Resistance3▲ 25×4 topics
  9. Infectious Diseases2▲ 27×2 topics
  10. Public Health2▲ 4.7×2 topics
  11. Antimicrobial Stewardship2▲ 207×1 topic
  12. Global Health2▲ 47×1 topic
  13. Neurotransmission2▲ 45×1 topic
  14. Synaptic Plasticity2▲ 19×1 topic
  15. Immune Response2▲ 7.4×4 topics
  16. Microbial Communities2▲ 12×2 topics
  17. Environmental Impact1▲ 3.0×2 topics
  18. Antibiotics1▲ 47×1 topic
  19. Antiviral Therapy1▲ 24×2 topics
  20. Crystal Structure1▲ 14×2 topics
  21. Drug Discovery1▲ 9.0×3 topics
  22. Genomics1▲ 9.9×4 topics
  23. Liver Disease1▲ 27×2 topics
  24. Resistance Genes1▲ 96×1 topic
  25. Signal Transduction1▲ 14×2 topics
  26. Cell Signaling1▲ 8.7×2 topics
  27. Treatment1▲ 2.4×5 topics
  28. Hepatocellular Carcinoma1▲ 13×2 topics
  29. Inflammation1▲ 1.21×7 topics

Which research topics does VenatoRx Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy, Antibiotic Use and Resistance and Urinary Tract Infections Management.

  1. 1 Antibiotic Resistance in Bacteria Molecular Medicine 4 works
  2. 2 Antibiotics Pharmacokinetics and Efficacy Pharmacology 4 works
  3. 3 Antibiotic Use and Resistance Applied Microbiology and Biotechnology 1 works
  4. 4 Urinary Tract Infections Management Epidemiology 1 works
  5. 5 Pharmaceutical and Antibiotic Environmental Impacts Pollution 0 works
  6. 6 Pneumonia and Respiratory Infections Epidemiology 0 works
  7. 7 Plant Pathogenic Bacteria Studies Plant Science 0 works
  8. 8 Infections and bacterial resistance Endocrinology 0 works
  9. 9 Bacterial Genetics and Biotechnology Genetics 0 works
  10. 10 Pharmacological Effects and Toxicity Studies Pediatrics, Perinatology and Child Health 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available76.1%not open23.9%

World: 40% of research is openly available.

with international co-authors21.7%domestic only78.3%

World: 18% is written across borders.

How has VenatoRx Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 174% higher than in 2018-2021.

still counting200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is VenatoRx Pharmaceuticals (United States) as a percentage of every work published that year, 0.000020% in 2024.

still counting0.00010%0.00020%0.00030%VenatoRx Pharmaceuticals (United States)0.00018% in 2025200020102020

Fractional works of VenatoRx Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Malvern

All research institutions in Malvern

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about VenatoRx Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.